touchONCOLOGY joins Dr Elena Garralda (Vall d’Hebron Institute of Oncology, Barcelona, Spain) at ASCO 2021 to discuss favezelimab in metastatic colorectal cancer.
The abstract ‘A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer (NCT02720068)’ (abstract number 3584) was presented at the 2021 ASCO Annual Meeting.
Citation: J Clin Oncol 39, 2021 (suppl 15; abstr 3584)
1. What is favezelimab (MK4280) and its mechanism of action? (00:14-00:39)
2. What was the rationale for using favezelimab in combination with pembrolizumab in patients with microsatellite stable metastatic colorectal cancer that had progressed on two or more prior therapies? (00:39-01:33)
3. Could you give us an overview of the phase I study and its findings? (01:33-03:08)
4. Which patients had the best response to this combination? (03:08-03:30)
5. What will be the next steps in the clinical development of favezelimab in this treatment setting? (03:30-04:08)
6. What do you think is the most important aspect to consider with regards to immunotherapy in this patient subset? (04:08-04:42)
Disclosures: Research: Novartis, Roche, Thermo Fisher, AstraZeneca, Taiho, BeiGene. Consultant/Advisor: Roche/Genentech, F.Hoffmann/La Roche, Ellipses Pharma, Neomed Therapeutics1 Inc, Boehringer Ingelheim, Janssen Global Services, SeaGen, TFS, Alkermes, Thermo Fisher, Bristol-Mayers Squibb, MabDiscovery, Anaveon. Travel Grants: Bristol-Mayers Squibb, Merck Sharp & Dohme, Menarini, Glycotope. Speakers Bureau: Merck Sharp & Dohme, Roche, Thermo Fisher, Lilly. Clinical Trials PI or Co-PI (Institution): Affimed Gmbh, Amgen SA, Anaveon AG, AstraZeneca AB, Biontech Gmbh, Catalym Gmbh, Cytomx, F.Hoffmann, La Roche Ltd, F-Star Beta Limited, Genentech Inc, Genmab B.V., Hutchison Medipharma Limited, Icon, Imcheck Therapeutics, Immunocore Ltd, Janssen-Cilag SA, Medimmune Llc, Merck Kgga, Novartis Farmacéutica, S.A, Peptomyc, Ribon Therapeutics, Roche Farma SA, Seattle Genetics Inc, Symphogen A/S, Taiho Pharma Usa Inc.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Helen Fowler.
Filmed in coverage of the 2021 ASCO Annual Meeting.
Share this Video
Related Videos In Colorectal Cancer
Benjamin Weingberg, ASCO 2022: Highlights of ASCO in colorectal cancer, dostarlimab and the DYNAMIC study
Professor Benjamin Weinberg (Georgetown University, Washington, DC, USA) discusses the highlights of colorectal cancer at ASCO 2022. A subset of colorectal cancer is mismatch repair deficient and is responsive to PD-1 blockade in the metastatic setting. This led to the phase II study where dostarlimab, an anti PD-1 monoclonal antibody, was administered to patients with […]
Benjamin Weingberg, ASCO 2022: Highlights of ASCO in colorectal cancer, the PARADIGM study
PARADIGM is the first prospective trial to examine panitumumab versus bevacizumab in colorectal cancer. Professor Benjamin Weinberg (Georgetown University, Washington, DC, USA) discusses the findings of the phase III PARADIGM study in patients with RAS wild-type (WT) metastatic colorectal cancer. The abstract entitled ‘Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment […]
Takayuki Yoshino, ASCO 2022: PARADIGM trial of panitumumab plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 as first-line treatment in patients with MCRC
Dr Takayuki Yoshino (National Cancer Center Hospital East, Chiba, Japan) discusses the findings from the phase 3 PARADIGM trial, which was part of a plenary session and selected as one of the top abstracts from the conference. The trial assessed panitumumab plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 as first-line treatment in patients with RAS wild-type […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!